Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.

Nature neuroscience | 2014

Leucine-rich repeat kinase 2 (LRRK2) is enriched in the striatal projection neurons (SPNs). We found that LRRK2 negatively regulates protein kinase A (PKA) activity in the SPNs during synaptogenesis and in response to dopamine receptor Drd1 activation. LRRK2 interacted with PKA regulatory subunit IIβ (PKARIIβ). A lack of LRRK2 promoted the synaptic translocation of PKA and increased PKA-mediated phosphorylation of actin-disassembling enzyme cofilin and glutamate receptor GluR1, resulting in abnormal synaptogenesis and transmission in the developing SPNs. Furthermore, PKA-dependent phosphorylation of GluR1 was also aberrantly enhanced in the striatum of young and aged Lrrk2(-/-) mice after treatment with a Drd1 agonist. Notably, a Parkinson's disease-related Lrrk2 R1441C missense mutation that impaired the interaction of LRRK2 with PKARIIβ also induced excessive PKA activity in the SPNs. Our findings reveal a previously unknown regulatory role for LRRK2 in PKA signaling and suggest a pathogenic mechanism of SPN dysfunction in Parkinson's disease.

Pubmed ID: 24464040 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

Associated grants

  • Agency: Intramural NIH HHS, United States
    Id: ZIA AG000959-06
  • Agency: Intramural NIH HHS, United States
    Id: ZIA AG000944-06
  • Agency: Intramural NIH HHS, United States
    Id: Z01 AG000959-04
  • Agency: Intramural NIH HHS, United States
    Id: ZIA AG000944-05
  • Agency: NIA NIH HHS, United States
    Id: AG000928
  • Agency: Intramural NIH HHS, United States
    Id: ZIA AG000945-02
  • Agency: Intramural NIH HHS, United States
    Id: Z01 AG000944
  • Agency: Intramural NIH HHS, United States
    Id: ZIA AG000945-03
  • Agency: Intramural NIH HHS, United States
    Id: Z01 AG000944-01
  • Agency: Intramural NIH HHS, United States
    Id: Z01 AG000959-05
  • Agency: Intramural NIH HHS, United States
    Id: Z01 AG000945-01
  • Agency: Intramural NIH HHS, United States
    Id: ZIA AG000959-07
  • Agency: Intramural NIH HHS, United States
    Id: ZIA AG000944-04

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Lrrk2/Dardarin, N-terminus (antibody)

RRID:AB_10697869

This monoclonal targets Lrrk2/Dardarin N-terminus

View all literature mentions